Literature DB >> 15790930

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.

Reijiro Arakawa1, Norimasa Tamehiro, Tomoko Nishimaki-Mogami, Kazumitsu Ueda, Shinji Yokoyama.   

Abstract

OBJECTIVE: Fibrates are widely used drugs to reduce plasma triglyceride and increase high-density lipoprotein. Their active forms, fibric acids, are peroxisome proliferator-activated receptor-alpha activators, but no direct evidence has been demonstrated for their activation of ATP-binding cassette transporter A1 (ABCA1) in relation to clinically used fibrates. We investigated the reaction of fenofibric acid in this regard. METHODS AND
RESULTS: Fenofibric acid was examined for the effect of increase of ABCA1 activity. It enhanced ABCA1 gene transcription and its protein level in macrophage cell line cells and fibroblasts and increased apolipoprotein A-I-mediated cellular lipid release, all in a dose-dependent manner. Enhancement of the gene transcription was examined by using a reporter assay system for liver X receptor responsive element (LXRE) and its inactive mutant. The results demonstrated that the effect of fenofibric acid is dependent on active LXRE.
CONCLUSIONS: Fenofibric acid increased transcription of ABCA1 gene in a liver X receptor-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790930     DOI: 10.1161/01.ATV.0000163844.07815.c4

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  20 in total

Review 1.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Disambiguation of PharmGKB drug-disease relations with NDF-RT and SPL.

Authors:  Qian Zhu; Robert R Freimuth; Jyotishman Pathak; Matthew J Durski; Christopher G Chute
Journal:  J Biomed Inform       Date:  2013-05-29       Impact factor: 6.317

3.  Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.

Authors:  Michael Y Tsai; Jose M Ordovas; Na Li; Robert J Straka; Naomi Q Hanson; Valerie L Arends; Donna Arnett
Journal:  Mol Genet Metab       Date:  2010-03-06       Impact factor: 4.797

Review 4.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

5.  In vitro antimalarial activity and drug interactions of fenofibric acid.

Authors:  Rina P M Wong; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

6.  Biomolecular chemistry of isopropyl fibrates.

Authors:  Ganesaratnam K Balendiran; Niharika Rath; Amanda Kotheimer; Chad Miller; Matthias Zeller; Nigam P Rath
Journal:  J Pharm Sci       Date:  2012-01-13       Impact factor: 3.534

7.  Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway.

Authors:  Kazuhiro Nakaya; Junichiro Tohyama; Snehal U Naik; Hiroyuki Tanigawa; Colin MacPhee; Jeffrey T Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

Review 8.  Advances in the medical treatment of diabetic retinopathy.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Diabetes Care       Date:  2009-08       Impact factor: 17.152

9.  On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

Authors:  Masaki Ogata; Maki Tsujita; Mohammad Anwar Hossain; Nobukatsu Akita; Frank J Gonzalez; Bart Staels; Shogo Suzuki; Tatsuya Fukutomi; Genjiro Kimura; Shinji Yokoyama
Journal:  Atherosclerosis       Date:  2009-01-19       Impact factor: 5.162

10.  What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?

Authors:  Amita Singh; Arthur Schwartzbard; Eugenia Gianos; Jeffrey S Berger; Howard Weintraub
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.